Effect of D-glucose on intestinal permeability and its passive absorption in human small intestine in vivo
When available, third-party lab reports are published on product pages so laboratories can review them before ordering.
announced that its data from the 48-week IMPACT Phase 2b clinical trial on pemvidutide for treating metabolic dysfunction-associated steatohepatitis (MASH) will be presented at the EASL Congress 2026 in Barcelona
An analysis of the transcriptomic profile of RILI in non-human primates revealed that the expression of SERPINA3, ATP12A, GJB2, CLDN10, TOX3, and LPA was significantly up-regulated, suggesting their potential as biomarkers and therapeutic targets for RILI [103]
These methods allow for micronutrient stability and improved bioavailability, while also promoting the delivery of active ingredients to the intestinal sites of absorption in a sustained release fashion